Trial NCT04372706

View at ClinicalTrials.gov 
Org. Study IDs: RTX-240-01

Last trial update was posted on 2022-12-13

MeSH Interventions

Pembrolizumab

MeSH Conditions


Other Conditions

Solid Tumor, AML Adult

Stopping Reasons

Sponsor terminated study during expansion on 11/30/22. RTX-240 was well-tolerated in multiple indications, combinations, and dose levels (69pts). No DLTs, related deaths or SAEs were reported. RTX-240 cleared circulation rapidly.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID